![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF609 |
Gene summary for ZNF609 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF609 | Gene ID | 23060 |
Gene name | zinc finger protein 609 | |
Gene Alias | ZNF609 | |
Cytomap | 15q22.31 | |
Gene Type | protein-coding | GO ID | GO:0001764 | UniProtAcc | O15014 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23060 | ZNF609 | C51 | Human | Oral cavity | OSCC | 1.97e-03 | 4.04e-01 | 0.2674 |
23060 | ZNF609 | EOLP-1 | Human | Oral cavity | EOLP | 2.45e-19 | 5.15e-01 | -0.0202 |
23060 | ZNF609 | NEOLP-1 | Human | Oral cavity | NEOLP | 5.79e-10 | 5.26e-01 | -0.0194 |
23060 | ZNF609 | NEOLP-2 | Human | Oral cavity | NEOLP | 4.37e-05 | 3.25e-01 | -0.0196 |
23060 | ZNF609 | NEOLP-3 | Human | Oral cavity | NEOLP | 2.23e-07 | 3.17e-01 | -0.0191 |
23060 | ZNF609 | SYSMH1 | Human | Oral cavity | OSCC | 1.50e-03 | 1.50e-01 | 0.1127 |
23060 | ZNF609 | SYSMH2 | Human | Oral cavity | OSCC | 5.29e-06 | 2.13e-01 | 0.2326 |
23060 | ZNF609 | SYSMH3 | Human | Oral cavity | OSCC | 1.13e-11 | 4.13e-01 | 0.2442 |
23060 | ZNF609 | HTA12-15-2 | Human | Pancreas | PDAC | 6.19e-04 | 4.87e-01 | 0.2315 |
23060 | ZNF609 | HTA12-23-1 | Human | Pancreas | PDAC | 5.38e-05 | 8.03e-01 | 0.3405 |
23060 | ZNF609 | HTA12-25-1 | Human | Pancreas | PDAC | 1.01e-06 | 7.16e-01 | 0.313 |
23060 | ZNF609 | HTA12-26-1 | Human | Pancreas | PDAC | 7.04e-21 | 9.51e-01 | 0.3728 |
23060 | ZNF609 | HTA12-29-1 | Human | Pancreas | PDAC | 7.41e-38 | 8.51e-01 | 0.3722 |
23060 | ZNF609 | 047563_1562-all-cells | Human | Prostate | BPH | 1.10e-17 | 6.75e-01 | 0.0791 |
23060 | ZNF609 | 048752_1579-all-cells | Human | Prostate | BPH | 2.74e-50 | 8.33e-01 | 0.1008 |
23060 | ZNF609 | 052095_1628-all-cells | Human | Prostate | BPH | 3.15e-36 | 7.90e-01 | 0.1032 |
23060 | ZNF609 | 052097_1595-all-cells | Human | Prostate | BPH | 3.90e-49 | 8.24e-01 | 0.0972 |
23060 | ZNF609 | 052099_1652-all-cells | Human | Prostate | BPH | 6.61e-48 | 8.85e-01 | 0.1038 |
23060 | ZNF609 | Dong_P1 | Human | Prostate | Tumor | 4.81e-11 | 1.13e-01 | 0.035 |
23060 | ZNF609 | Dong_P3 | Human | Prostate | Tumor | 8.21e-03 | 4.73e-02 | 0.0278 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00075173 | Cervix | CC | muscle organ development | 58/2311 | 327/18723 | 2.73e-03 | 1.85e-02 | 58 |
GO:20012241 | Cervix | CC | positive regulation of neuron migration | 6/2311 | 16/18723 | 9.35e-03 | 4.66e-02 | 6 |
GO:00075174 | Endometrium | AEH | muscle organ development | 60/2100 | 327/18723 | 8.19e-05 | 1.22e-03 | 60 |
GO:00017642 | Endometrium | AEH | neuron migration | 31/2100 | 156/18723 | 1.08e-03 | 9.46e-03 | 31 |
GO:000751712 | Endometrium | EEC | muscle organ development | 59/2168 | 327/18723 | 3.49e-04 | 3.85e-03 | 59 |
GO:00017641 | Endometrium | EEC | neuron migration | 33/2168 | 156/18723 | 4.17e-04 | 4.38e-03 | 33 |
GO:2001224 | Liver | HCC | positive regulation of neuron migration | 14/7958 | 16/18723 | 2.73e-04 | 1.98e-03 | 14 |
GO:0001764 | Lung | IAC | neuron migration | 31/2061 | 156/18723 | 7.89e-04 | 1.02e-02 | 31 |
GO:0007517 | Lung | AAH | muscle organ development | 22/613 | 327/18723 | 1.20e-03 | 3.33e-02 | 22 |
GO:00075176 | Oral cavity | EOLP | muscle organ development | 57/2218 | 327/18723 | 1.76e-03 | 1.15e-02 | 57 |
GO:000751714 | Oral cavity | NEOLP | muscle organ development | 56/2005 | 327/18723 | 2.65e-04 | 2.70e-03 | 56 |
GO:00017643 | Oral cavity | NEOLP | neuron migration | 31/2005 | 156/18723 | 4.96e-04 | 4.40e-03 | 31 |
GO:00075175 | Prostate | BPH | muscle organ development | 71/3107 | 327/18723 | 9.00e-03 | 3.84e-02 | 71 |
GO:000751713 | Prostate | Tumor | muscle organ development | 74/3246 | 327/18723 | 8.03e-03 | 3.54e-02 | 74 |
GO:000751716 | Thyroid | ATC | muscle organ development | 139/6293 | 327/18723 | 4.45e-04 | 2.64e-03 | 139 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF609 | SNV | Missense_Mutation | c.781C>T | p.Pro261Ser | p.P261S | O15014 | protein_coding | deleterious(0.02) | probably_damaging(0.964) | TCGA-AN-A0AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF609 | SNV | Missense_Mutation | novel | c.457N>A | p.Val153Ile | p.V153I | O15014 | protein_coding | tolerated(0.32) | benign(0.003) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF609 | SNV | Missense_Mutation | c.952G>C | p.Val318Leu | p.V318L | O15014 | protein_coding | deleterious(0) | probably_damaging(0.935) | TCGA-D8-A1JT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
ZNF609 | SNV | Missense_Mutation | rs756586641 | c.389N>G | p.Asn130Ser | p.N130S | O15014 | protein_coding | tolerated(0.89) | benign(0.001) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD |
ZNF609 | SNV | Missense_Mutation | c.3647C>G | p.Ser1216Cys | p.S1216C | O15014 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
ZNF609 | SNV | Missense_Mutation | novel | c.3103N>T | p.Ala1035Ser | p.A1035S | O15014 | protein_coding | tolerated(1) | benign(0) | TCGA-E9-A3X8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphane | CR |
ZNF609 | SNV | Missense_Mutation | novel | c.164A>G | p.Lys55Arg | p.K55R | O15014 | protein_coding | tolerated(0.06) | probably_damaging(0.99) | TCGA-EW-A1P4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
ZNF609 | SNV | Missense_Mutation | novel | c.43N>A | p.Ala15Thr | p.A15T | O15014 | protein_coding | tolerated(0.27) | benign(0.005) | TCGA-OL-A97C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ZNF609 | insertion | Frame_Shift_Ins | novel | c.3302_3303insACAAGAAGGCAGAGATGGGCCTGAAGGAGCGG | p.Ser1102GlnfsTer17 | p.S1102Qfs*17 | O15014 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
ZNF609 | SNV | Missense_Mutation | novel | c.1160N>T | p.Ala387Val | p.A387V | O15014 | protein_coding | deleterious(0.04) | benign(0.017) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |